{"id":"ecc4703","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SGLT2 inhibitors like ECC4703 work by blocking the reabsorption of glucose in the kidneys, leading to reduced blood glucose levels. This can be beneficial for patients with type 2 diabetes. ECC4703 is being investigated for its potential to improve glycemic control in patients with type 2 diabetes.","oneSentence":"ECC4703 is a small molecule targeting the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:59:16.505Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07288138","phase":"PHASE2","title":"A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)","status":"RECRUITING","sponsor":"Eccogene","startDate":"2025-12-15","conditions":"Metabolic Dysfunction-associated Steatohepatitis","enrollment":160},{"nctId":"NCT07334080","phase":"PHASE1","title":"ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants","status":"RECRUITING","sponsor":"Eccogene","startDate":"2026-01-10","conditions":"Metabolic Dysfunction-Associated Steatohepatitis","enrollment":72},{"nctId":"NCT05552274","phase":"EARLY_PHASE1","title":"FTIH of ECC4703 in Healthy Volunteers","status":"COMPLETED","sponsor":"Eccogene","startDate":"2022-08-16","conditions":"Non-alcoholic Steatohepatitis (NASH)","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ECC4703","genericName":"ECC4703","companyName":"Eccogene","companyId":"eccogene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ECC4703 is a small molecule targeting the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}